UNITED STATES PATENT AND TRADEMARK OFFICE



Commissioner for Patents United States Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450

DEC 19 2011

Office of Regulatory Policy Food and Drug Administration 10903 New Hampshire Ave., Bldg. 51, Rm. 6222 Silver Spring, MD 20993-0002

Attention: Beverly Friedman

The attached application for patent term extension of U.S. Patent No. 7,090,843 was filed on October 13, 2011, under 35 U.S.C. § 156. Extension is sought based on the regulatory review of ADCETRISTM (brentuximab vedotin) in BLA 125388 for treatment of patients with Hodgkin Lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates.

The assistance of your Office is requested in confirming that the product identified in the application, ADCETRISTM (brentuximab vedotin), has been subject to a regulatory review period within the meaning of 35 U.S.C. § 156(g) before its first commercial marketing or use and that the application for patent term extension was filed within the sixty-day period beginning on the date the product was approved. Since a determination has not been made whether the patent in question claims a product which has been subject to the Federal Food, Drug and Cosmetic Act, or a method of manufacturing or use of such a product, this communication is NOT to be considered as notice which may be made in the future pursuant to 35 U.S.C. § 156(d)(2)(A).

Our review of the application to date indicates that the subject patent would be eligible for extension of the patent term under 35 U.S.C. § 156.

Inquiries regarding this communication should be directed to the undersigned at (571) 272-7755 (telephone) or (571) 273-7755 (facsimile).

Mary C. Till

Senior Legal Advisor

Office of Patent Legal Administration
Office of the Associate Commissioner
for Patent Examination Policy

cc: Mark Sandbaken Seattle Genetics, Inc. 21823 30th Drive SE Bothell, WA 98021